Kornimate/medical-research-clean huggingface dataset:
the relationship between morphology and virulent genes of candida albicans and clinical aspects, surveillance of fungemia

Conditions: Candidemia Prognostic Factor and Mycobiological Analysis.

Summary: candida albicans is the most common and important clinical fungal pathogen. our previous surveillance disclosed that fluconazole could induce different morphological changes in clinical strains. our current study on c. albicans causing candiuria disclosed that renal insufficiency , diabetes mellitus, respiratory failure and uremia were risk factors of treatment failure. however, we also found results of e-test drug susceptible test could not predict outcome. hence, retrospective analysis of 31 months period, cases that had c. albicans inducing candidemia were reviewed and 60 cases were enrolled for morphological study and potential virulent gene analysis. this study is designed to clarity the clinical meaning of morphological form and virulent genes on candidemia. to do this study is probably helpful for treatment of candidiasis.


Eligibility criteria:
inclusion criteria: * 2007 to 2010 medical records * cases with candidemmia of candida albicans with available clinical information in medical records for analysis. * cases with candidemmia of candida albicans which clinical isolates were preserved. exclusion criteria: * cases were not hospitalized for treatment and data were not available for analysis.

Keywords: candida albicans, fungemia , prognostic factor
soft tissue response to different restorative materials used in implant dentistry

Conditions: Edentulous Alveolar Ridge; Peri-Implantitis; Peri-implant Mucositis; Prosthetic Infection; Prosthetic Complication

Summary: the goal of this clinical trial is to learn how different materials used in dental implants affect the surrounding gum tissue in adults who need dental implants. the main questions it aims to answer are: how do different materials (titanium, peek, zirconia, and lithium disilicate) affect inflammation around dental implants? what changes occur in inflammation markers in the gum tissue after 3 and 6 months? researchers will compare the different materials to see which one causes the least amount of inflammation. participants will: receive dental implants made from different materials. have samples of fluid from around their implants collected for analysis at 3 and 6 months. undergo regular dental check-ups to measure gum health, such as bleeding and pocket depth around the implants.

the study will involve a total of 40 edentulous patients, each missing four teeth in the posterior region of the mandible or maxillae. each patient will receive four dental implants and single crowns made from different materials. the primary objectives are to evaluate biomarkers in peri-implant crevicular fluid and to assess the changes in these biomarkers after three and six months of loading. this research will help determine the biocompatibility of the materials and their potential to cause peri-implantitis.

Eligibility criteria:
inclusion criteria: * participants must be 18 years or older. * participants must be edentulous with at least four missing teeth in the posterior region of the mandible or maxillae. * participants must have appropriate oral hygiene and periodontal status of natural teeth, with a pocket depth of 4mm or less and no bleeding. * dental implants must be fully integrated with no bone resorption or inflammation after three months of implant placement, confirmed by x-ray and clinical examination. * implant placement must be into natural bone without additional procedures such as sinus lift or bone augmentation. * the procedure must be a standard implantation with no immediate implant placement. * the height of the gingiva must be at least 3mm or more. exclusion criteria: * patients with systemic diseases such as malignancy, diabetes, osteoporosis, or rheumatoid arthritis. * patients with a history of periodontal treatment. * patients who smoke or use tobacco. * patients who have received antibiotic treatment within three months prior to implantation. * pregnant individuals.

Keywords: dental implants peri-implant soft tissue prosthetic materials inflammation markers oral health
a study comparing infusion rates of tocilizumab in patients with moderate to severe rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this 2 arm study will compare the incidence of tocilizumab-related infusion reactions, using 2 different infusion times, in patients with moderate to severe rheumatoid arthritis who have shown an inadequate response to dmards (disease modifying anti rheumatic drugs) or anti-tnfs.patients will be randomized to one of 2 groups, to receive tocilizumab 8mg/kg iv every 4 weeks either a)over a 1h infusion time for all administrations or b) a 1h infusion time for the first administration, followed by a 31 minute infusion time for subsequent administrations (unless drug-related infusion reactions occur).the anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * active moderate or severe rheumatoid arthritis; * active disease for \>6 months; * inadequate response to a stable dose of non-biologic dmards or antitnfs. exclusion criteria: * rheumatic autoimmune disease other than rheumatoid arthritis; * prior history of, or current inflammatory joint disease other than rheumatoid arthritis; * major surgery (including joint surgery) within 8 weeks prior to screening, or planned major surgery within 6 months following enrollment.
immunoglobulin for hypogammaglobulinemia due to chimeric antigen receptor t cell therapy

Conditions: Hypogammaglobulinemia, Acquired

Summary: chimeric antigen receptor (car) t cells are special immune cells taken from a patient and changed in a lab to help them find and attack cancer cells. these cells are designed to look for a marker called cd19, which is found on both cancer cells and healthy b cells (a type of white blood cell). because of this, car t cells can also destroy healthy b cells. this can lead to a strong drop in b cells and cause a condition called hypogammaglobulinemia (hgg), which makes it harder for the body to fight infections. serious infections are common in people treated with car t cells and are a major reason for death that is not caused by the return of cancer. to help prevent infections, patients with hgg often get immunoglobulin replacement therapy (irt), which gives them the antibodies they need. this treatment can be given through a vein (ivig) or under the skin (scig). the goal of this project is to study how often these patients get bacterial infections, how they feel about their quality of life and treatment, and what side effects they may have when treated with ivig or scig after car t-cell therapy.

chimeric antigen receptor (car) t cells are patient-derived t cells engineered to express a fusion protein that directs them to target a tumor-associated antigen. the tumor-associated antigen cd19 is expressed on tumor cells in these conditions as well as on healthy cells of the b cell lineage. this results the "on-target off-tumor" effect of profound b cell depletion in these patients often with attendant hypogammaglobulinemia (hgg). serious infections are common in this patient population and represent the main cause of non-relapse related mortality in car t cell treated patients. treatment of hgg with immunoglobulin replacement therapy (irt) is a core component of infection prevention. standard of care irt can be administered intravenously (ivig) or subcutaneously (scig). the proposed project will investigate frequency of bacterial infections, quality of life, treatment satisfaction, and adverse events in patients treated with car t-cell therapy who are treated with ivig and scig.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. severe hgg defined as total igg \<4 g/l (after subtracting the igg paraprotein fraction, if present) 3. treated with cd19 targeted car t cell therapy in the past 6 months 4. consent to receive plasma-derived productions 5. ability to provide informed consent exclusion criteria: 1. inability to comply with study procedures 2. pregnancy or planning to conceive 3. breastfeeding 4. protein-losing conditions that may contribute to hgg (e.g., protein-losing enteropathy, nephrotic syndrome) 5. scig infusion in the prior 3 months. 6. history of allergy or severe reactions to immune globulin productions

Keywords: secondary immunodeficiency car t immune globulin
the breast program - translational cancer resource

Conditions: Breast Cancer

Summary: tracr will provide a data/biospecimen repository for translational research to better diagnose, prognose, treat and cure breast cancer (and related diseases/treatment conditions). patients at the rowan breast center will be consented for donation of blood and if available tumor/healthy/archived tissue. patients will be consented to give permission to use said specimens for future research and to be contacted in the future about other research participation and additional information.


Eligibility criteria:
inclusion criteria: * rbc patients with known invasive cancer pre-surgery (greater or equal to 1.5cm) are given priority in recruitment. * rbc patients with known invasive cancer pre-surgery (less then 1.5cm). 3. rbc patients who are postsurgery for invasive breast cancer (performed at uphs or non-uphs entities). * patients that are of high risk for breast cancer (family history, known deleterious genetic mutation(s)) seeking a prophylactic mastectomy at the breast clinic. * only persons who can understand and give informed consent will be eligible to participate in this study. furthermore, no persons belonging to vulnerable populations with as children (below 18 years of age), fetuses, neonates or prisoners will be recruited in this study. pregnant women, who are pre-surgery and having surgery for clinical reasons, can still be recruited for tissue and blood collection. exclusion criteria: * individual who cannot understand and give informed consent (cognitively impaired persons) * children (below 18 years of age), fetuses and neonates * prisoners
effect of aerobic training on sleep problems and pulmonary functions in children with down syndrome

Conditions: Down Syndrome

Summary: the study will be conducted to determine the effect of aerobic training on sleep problems and pulmonary functions in children with down syndrome.

the study will be carried out on 30 children with down syndrome (trisomy 21) of both sexes, with ages ranging from 7 to 12 years old. children will be recruited from schools for children with special needs. children will be randomly assigned into two equal groups (control and study groups), 15 for each group. the control group will receive a selected physical therapy program only, while the study group will receive the same selected physical therapy program as the control group in addition to aerobic exercise in the form of treadmill training. the arabic version of the children's sleep habits questionnaire (cshq) will be used to assess sleep problems, while a handheld spirometer will be used to assess pulmonary functions (forced vital capacity (fvc), forced expiratory volume in 1 second (fev1), fev1/fvc ratio, and peak expiratory flow rate (pefr)) pre- and post-intervention.

Eligibility criteria:
inclusion criteria: * children with down syndrome (trisomy 21). * their ages range from 7 to 12 years old. * both sexes will be included. * children should be able to understand and follow simple verbal commands or instructions (intelligence quotient (iq) range: 50-70). * children should be able to walk independently. * their total scores on the arabic version of the children's sleep habits questionnaire (cshq) equal 41 or higher. exclusion criteria: children will be excluded from the study if they: * have visual or hearing defects. * have spinal abnormality such as kyphosis and scoliosis. * have history of pulmonary infection and surgery of thoracic and abdominal region within the past 6 months. * play any specific sport or exercises. * have physical activity restrictions. * have musculoskeletal disorder. * take medications known to affect sleep.

Keywords: aerobic training treadmill training sleep sleep problems sleep disturbances obstructive sleep apnea (osa) pulmonary functions down syndrome trisomy 21 children's sleep habits questionnaire (cshq) handheld spirometer
cytokine in cerebrospinal fluid (csf) from multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is an inflammatory disease of the brain leading to disability. brain mri is very useful for ms diagnosis but prognostic biomarkers are still needed. new therapies are also expected to improve ms care. cytokine arrays provide measure of many different inflammation-related molecules that could help understanding the disease. moreover, individual prognosis could be linked with the level of such molecules in the csf of ms patients. the investigators will analyze the cytokine profile of ms and control patients csf to determine a specific profile of ms and look for prognosis implication in a cohort of patients with clinically isolated syndromes (first manifesatation of ms).

multiple sclerosis (ms) is an inflammatory disease of the brain leading to disability. early treatment could allow better prognosis for the patients in the long term by reducing relapses rates and neurological palsy. however, individual prognostic biomarkers are still needed to adapt the treatment to a given patient. csf is a strategic body fluid to explore in neurological diseases. in ms, it contains an elevated igg index and/or oligoclonal bands reflecting the intrathecal synthesis of igs around the brain. the levels of other inflammatory molecules such cytokines and metalloproteases are also known to be elevated in ms (gm-csf, il-6, il-10, mmp-2, mmp9, timp-1, tnf-α, rantes, mcp-1 and mip-1). these molecules can now be easily measured by protein arrays.the aim of this study is to measure the level of 40 cytokines and 10 mmps by means of protein arrays in the csf from clinically definite ms (cdms) patients, control patients and patients with a clinically isolated syndrome (cis). the best ms markers will be determined using multiple roc curves. markers of rapid conversion to cdms after a cis will also be looked for.the best ms candidate biomarkers will be analyzed by elisa in a new cohort of patients being recruited.

Eligibility criteria:
inclusion criteria: * clinically definite multiple sclerosis patients (at least 2 relapses) * patient having presented another neurological episode suggestive of multiple sclerosis confirmed or not by a neurologist and allowing to establish the diagnosis of multiple sclerosis according to the criteria of mc donald * age ≥ 18 years * patients informed about the objectives of the study and about its practical realization exclusion criteria: * patient having received a treatment by corticoids in 30 days before the lumbar puncture * contraindication of the lumbar puncture such as an anticoagulating oral treatment for example * pregnancy

Keywords: multiple sclerosiscerebrospinal fluidbiomarkercytokinearray
effect of dual task on upper and lower extremity skills in parkinson's disease

Conditions: Parkinson Disease; Movement Disorders

Summary: the aim of the study is to investigate the change of lower and upper extremity skills with dual task in parkinson's disease patients and to determine the differences between parkinson's disease patients with different stages of disease and the healthy controls regarding the change of lower and upper extremity skills with dual task.


Eligibility criteria:
inclusion criteria: * modified hoehn \& yahr (h\&y) stages 1 to 3 * at least 40 years of age * 21 or more moca score. exclusion criteria: * other neurologic disorder * any orthopedic problem that could prevent to participate in the study * severe dyskinesia or tremor * visual or speech problems
mri and computational simulation cardiology study

Conditions: Congenital Heart Disease; Pulmonary Hypertension

Summary: the purpose of this study is to (1) quantify cardiovascular anatomy and physiology using magnetic resonance imaging under both resting and exercise conditions in patients who have congenital heart disease and in age-matched normal volunteers, (2) use computer models to reproduce and simulate blood flow in these patients, and then (3) to combine the imaging data and computer models to estimate values which cannot be directly measured and to predict physiological changes induced by exercise and medical or surgical therapies.

investigators hope to gain a greater understanding of the hemodynamics of congenital heart disease and their associated operations as they pertain to real-life situations (i.e. upright and non-sedentary, rest and exercise). with this knowledge, investigators would look to optimize the geometry and physiology of the patients, potentially reducing several of the long-term complications found in congenital heart disease patients such as cardiomyopathy, pulmonary hypertension, arrhythmias, thrombosis and heart failure.

Eligibility criteria:
inclusion criteria: * patients will have congenital heart disease or acquired cardiopulmonary disease. * normal volunteers will be willing to undergo mri exclusion criteria: * patients unable to receive intravenous contrast material (this does not apply to normal volunteers) * subjects with arrhythmias which will prevent mri cardiac gating * subjects with illnesses which make participation inappropriate. in addition, patients who would normally be excluded from an mri study because of pacemaker implant, aneurysm clip, severe claustrophobia, or any other condition which, based on the investigator's judgment, would preclude proximity to a strong magnetic field will be excluded from this study as well. * normal volunteers may be excluded if they are not able to remain still during the exam or follow the instructions of the investigators.
investigation of memantine in the treatment of memory, concentration or attention problems

Conditions: Memory Disorder; Retention Disorder, Cognitive; Subjective Cognitive Impairment; Memory, Concentration or Attention Problems

Summary: in this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.


Eligibility criteria:
inclusion criteria: * subjective worsening of memory, concentration or attention problems for longer than 6 months * subject can confirm that a relative or friend has noticed the memory, concentration or attention problems of the subject * experience of the memory, concentration or attention problems at least four times per week exclusion criteria: * significant neurological disease or major psychiatric disorder (e.g. diagnosis of psychosis or dementia) * significant systemic illness, such as cancer, heart or kidney failure, uncontrolled diabetes * history of stroke or seizure, or myocardial infarction within the last year (e.g. by inclusion questionnaire, physician interview)
the effects of ballet-based exercise training on respiratory functions, balance, cognitive functions, peripheral muscle strength, functional capacity and quality of life in patients with parkinson's disease

Conditions: Parkinson&#39;s Disease (PD)

Summary: this study investigates the impact of an 8-week ballet-based dance therapy on people with parkinson's disease. it aims to assess the effect of ballet on motor and non-motor symptoms, such as balance, cognitive function, functional capacity, and quality of life. the study will provide insights into the potential of ballet therapy as an effective, non-pharmacological treatment for parkinson's disease.

this clinical trial aims to evaluate the effects of an 8-week ballet-based dance therapy on individuals with parkinson's disease. the intervention will target motor and non-motor symptoms, including functional capacity, balance, cognitive function, and quality of life. participants will be randomly assigned to either the intervention group or a control group. the intervention group will engage in structured ballet classes, while the control group will receive standard care. assessments will include measures of respiratory function, body composition, muscle strength, and balance, with evaluations conducted before and after the intervention. the goal is to assess the feasibility and effectiveness of ballet as a therapeutic approach to improve both physical and mental well-being in people with parkinson's disease.

Eligibility criteria:
inclusion criteria: * age 18 years or older. * diagnosed with parkinson's disease. * modified hoehn and yahr stages i to iii. * willingness to participate and provide informed consent. exclusion criteria: * joint deformities or severe movement limitations that prevent participation in dance exercises. * mental retardation (severe cognitive impairment). * major surgery within the past 6 months. * presence of uncontrolled cardiovascular, pulmonary, or oncological diseases. * diagnosed visual or auditory impairments affecting balance.

Keywords: ballet-based dance therapy respiratory function balance cognitive function quality of life
efficacy, safety and cost-effectiveness of peg-rhg-csf for primary vs secondary prophylaxis

Conditions: Chemotherapy-induced Neutropenia

Summary: this trial is a multicenter, non-interventional, registered real-world clinical study. based on available evidence and recommendations of guidelines, tumor patients with high risk of fn and eligible for all enrollment criteria were recruited into primary prophylaxis of peg-rhg-csf or secondary prophylaxis of peg-rhg-csf according to the real-world clinical pathway without randomization. all patients need to receive at least 2 cycles of peg-rhg-csf prophylaxis. researchers will record the incidence of fn, rdi, fn-related hospitalization, antibiotic use, direct medical care and indirect medical care cost under the real clinical conditions, and assess the efficacy, safety and cost-effectiveness of peg-rhg-csf primary prophylaxis versus secondary prophylaxis through sub-group analysis and exploratory research.

patients with cancer planning for chemotherapy assessed with high risk of febrile neutropenia (fn) according to nccn and asco guidelines are recruited, receiving primary or secondary prophylaxis of peg-rhg-csf according to real-world clinical pathway in local cancer center for at least 4 cycles of chemotherapy. the primary outcome is the incidence of fn rate and proportion of patients completing chemotherapy on schedule, the second outcomes are the incidence of 3-4 grade of neutropenia, fn-related hospitalization and antibiotic use, incidence of reduction and delay of chemotherapy dose, safety and pharmacoeconomics of peg-rhg-csf.

Eligibility criteria:
inclusion criteria: 1. before the start of the study, all patients have been fully understood the research and the must sign the informed consent 2. aged 13 years or older 3. accept at least 4 cycles of chemotherapy 4. ecog ps 0-2 5. expected survival time ≥ 3 months 6. with -high risk of fn according to researchers exclusion criteria: 1. accepted stem cell or bone marrow transplant 2. undergoing any other clinical trial 3. uncontrolled infection, temperature≥38℃ 4. per-week scheme chemotherapy 5. severe and uncontrolled diabetes 6. people with allergic diseases or allergies, or who are allergic to this or other genetically engineered escherichia coli-derived biological products 7. suspected or confirmed drug use, drug abuse, alcoholics 8. severe mental or neurological disorders affecting informed consent and/or adverse effect presentation or observation 9. severe heart, kidney, liver and other important organs chronic diseases 10. pregnancy or lactation in women or women with gestation detection positive before the first time using drug 11. patients who have fertility but are unwilling to receive contraception or partners are not willing to accept contraceptives 12. the investigator believes that the patient's condition is not suitable for this clinical study.